Literature DB >> 11896097

Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.

M Margaret Kemeny1, Sudeshna Adak, Bruce Gray, John S Macdonald, Thomas Smith, Stuart Lipsitz, Elin R Sigurdson, Peter J O'Dwyer, Al B Benson.   

Abstract

PURPOSE: Despite technical improvements that have minimized the morbidity and mortality of hepatic surgery, the long-term outcome of resection of hepatic metastases of colorectal cancer remains poor, with the majority of patients experiencing treatment failure in the liver. Because arterial chemotherapy regimens targeted to the liver have demonstrated high response rates, an intergroup trial of adjuvant therapy for patients undergoing hepatic resection of liver metastases from colorectal cancer was initiated. PATIENTS AND METHODS: Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients). After exclusion of patients identified as ineligible for the planned treatment at the time of surgery, there were 45 control patients and 30 on the chemotherapy arm. The study was powered to evaluate improvement in time to recurrence and hepatic disease-free survival, not overall survival.
RESULTS: The 4-year recurrence-free rate was 25% for the control arm and 46% for the chemotherapy group (P =.04). The 4-year liver recurrence-free rate was 43% in the control group and 67% in the chemotherapy group (P =.03). The median survival of the 75 assessable patients was 49 months for the control arm and 63.7 months for the chemotherapy arm (P =.60). The median survival of all 109 patients was 47 months for the control arm compared with 34 months for the chemotherapy arm (P =.19)
CONCLUSION: These data demonstrate that adjuvant intra-arterial and intravenous chemotherapy was beneficial in prolonging time to recurrence and pre-venting hepatic recurrence after hepatic resection of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896097     DOI: 10.1200/JCO.2002.20.6.1499

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  92 in total

Review 1.  [Palliative treatment for colorectal cancer].

Authors:  D Flieger; R Keller; W Fischbach
Journal:  Internist (Berl)       Date:  2004-07       Impact factor: 0.743

Review 2.  Current treatment for colorectal liver metastases.

Authors:  Evangelos P Misiakos; Nikolaos P Karidis; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

Review 3.  Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.

Authors:  Santiago Aparo; Sanjay Goel
Journal:  Crit Rev Oncol Hematol       Date:  2011-09-23       Impact factor: 6.312

4.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

5.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

6.  Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.

Authors:  Nancy E Kemeny; William R Jarnagin; Marinela Capanu; Yuman Fong; Alexandra N Gewirtz; Ronald P Dematteo; Michael I D'Angelica
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

7.  Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials.

Authors:  Thomas E Clancy; Elijah Dixon; Roy Perlis; Francis R Sutherland; Michael J Zinner
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

8.  Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

Authors:  Nir Lubezky; Ravit Geva; Einat Shmueli; Richard Nakache; Joseph M Klausner; Arie Figer; Menahem Ben-Haim
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

9.  Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era.

Authors:  Y J Ko; P J Karanicolas
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

10.  Multicentre results of stereotactic body radiotherapy for secondary liver tumours.

Authors:  Betul Berber; Rafael Ibarra; Laura Snyder; Min Yao; Jeffrey Fabien; Michael T Milano; Alan W Katz; Karyn Goodman; Kevin Stephans; Galal El-Gazzaz; Federico Aucejo; Charles Miller; John Fung; Simon Lo; Mitchell Machtay; Juan Sanabria
Journal:  HPB (Oxford)       Date:  2013-01-14       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.